Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years
Open accessThe DOI matches its Crossref record; 195 of the 196 references it cites were found in a registry or an index.
Abstract
To date, pharmacological treatments for mood and anxiety disorders and for drug dependence show limited efficacy, leaving a large number of patients suffering severe and persistent symptoms. Preliminary studies in animals and humans suggest that ayahuasca, psilocybin and lysergic acid diethylamide (LSD) may have antidepressive, anxiolytic, and antiaddictive properties. Thus, we conducted a systematic review of clinical trials published from 1990 until 2015, assessing these therapeutic properties. Electronic searches were performed using the PubMed, LILACS, and SciELO databases. Only clinical trials published in peer-reviewed journals were included. Of these, 151 studies were identified, of which six met the established criteria. Reviewed studies suggest beneficial effects for treatment-resistant depression, anxiety and depression associated with life-threatening diseases, and tobacco and alcohol dependence. All drugs were well tolerated. In conclusion, ayahuasca, psilocybin and LSD may be useful pharmacological tools for the treatment of drug dependence, and anxiety and mood disorders, especially in treatment-resistant patients. These drugs may also be useful pharmacological tools to understand psychiatric disorders and to develop new therapeutic agents. However, all studies reviewed had small sample sizes, and half of them were open-label, proof-of-concept studies. Randomized, double-blind, placebo-controlled studies with more patients are needed to replicate these preliminary findings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“they also appear to have broad therapeutic potential, demonstrating efficacy for treating depression, post-traumatic stress disorder (PTSD), anxiety disorders, substance abuse disorder, and alcohol use disorder, among others”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [171]
In the citing paper
“these medicines have demonstrated efficacy across a range of neuropsychiatric disorders including depression, PTSD, and addiction (156, 168–172)”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [171]
In the citing paper
“Most of these studies however suffer from low methodological validity and are mostly open-label, yet they have yielded preliminary evidence for the capacity of psychedelic substances for treating addiction, depression, anxiety, and eating disorders (29–35).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [31]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Research works printed but not linked: 16
- Furst P., 1994, Alucinógenos y cultura
- Grob C., 1998, Heffter Rev Psychedelic Res, 1, 8
- Grof S., 2001, LSD psychotherapy
- Halpern J., 2008, Med Sci Monit, 14, SR15
- Harner M., 1976, Alucinógenos y chamanismo
- Hintzen A., 2010, The pharmacology of lysergic acid diethylamide: a critical review
- Hofmann A., 2005, LSD: my problem child
- House R., 1997, NIDA Res Monogr, 173, 175
- Labate B., 2009, Ayahuasca religions: a comprehensive bibliography and critical essays
- Lima L., 2006, Ärztez Naturheilverfahren, 47, 476
- Ott J., 1994, Ayahuasca analogues: pangaean entheogens
- Ott J., 2004, Pharmacotheon: drogas enteogénicas, sus fuentes vegetales y su historia
- Réus G., 2012, Depress Res Treat, 2012, 987397
- Schultes R., 1986, Am Indig, 46, 9
- Schultes R., 1998, Heffter Rev Psychedel Res, 1, 1
- Sos P., 2013, Neuro Endocrinol Lett, 34, 287
Cited by
Items 201–300 of 307
Ginati, Y. D., Madjar, N., Ben-Sheetrit, J., Lev‐Ran, S., Weizman, A., & Shoval, G. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.1941444 · Cited by 5
“In psychiatry, LSD was studied as a possible treatment mostly for depression, anxiety, substance abuse or addictions (Das et al. 2016; dos Santos et al. 2016).”
BackgroundArgento, E., Goldenberg, S. M., Deering, K., Lavalley, J., Braschel, M. C., Bingham, B., & Shannon, K. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100044 · Cited by 7
Pasculli, G., Busan, P., Jackson, E. S., Alm, P. A., Gregorio, D. D., Maguire, G. A., Goodwin, G. M., Gobbi, G., Erritzøe, D., & Carhart-Harris, R. L. (2024) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2024.1402549 · Cited by 7
Walker, C., Piatkowski, T. M., Ferris, J., Davies, E., Barratt, M. J., WINSTOCK, A. R., & Puljević, C. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241265762 · Cited by 6
“Psychedelics also exhibit good tolerability and safety profiles in clinical settings (Andersen et al., 2021; Dos Santos et al., 2016), while non-clinical studies associate them with positive behaviour change and improved well-being (Garcia-Romeu and Richards, 2018; Jungaberle et al., 2018; Nayak et…”
BackgroundGlennon, R. A., & Iversen, L. L. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc101.pub3 · Cited by 5
Microdosing Psychedelics as a Promising New Pharmacotherapeutic
Kuypers, K. P. C. (2021) · Springer eBooks · doi:10.1007/978-3-030-62351-7_18 · Cited by 5
Potential Anti-Depressive Treatment Maneuvers from Bench to Bedside
Cai, M., Wang, H., & Zhang, X. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9271-0_15 · Cited by 7
da Cruz, R. V. L., Moulin, T. C., Petiz, L. L., & Leão, R. N. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00079 · Cited by 7
Gold, N. D., Podrebarac, S. K., White, L. A., Marini, C., Simon, N. M., Mittelman, M. S., Ross, S., Bogenschutz, M. P., & Petridis, P. D. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2022.0011 · Cited by 3
“153 The most commonly reported side effects include bodily discomforts such as headaches and nausea 154 as well as transient increases in heart rate and blood pressure.”
Traditional Amazonian medicine in addiction treatment: Qualitative results
O’Shaughnessy, D. M., Sarnyai, Z., Quirk, F. H., & Rodd, R. (2022) · SSM - Qualitative Research in Health · doi:10.1016/j.ssmqr.2022.100086 · Cited by 4
Information parity increases on functional brain networks under influence of a psychedelic substance
Viol, A., Viswanathan, G. M., Soldatkina, O., Palhano-Fontes, F., Onias, H., de Araújo, D. B., & Hövel, P. (2023) · Journal of Physics Complexity · doi:10.1088/2632-072x/acc22b · Cited by 4
Microdosing psychedelics has no impact on cognitive function in naturalistic settings
Dinkelacker, J., & Pop, I. (2023) · Journal of Psychology & Clinical Psychiatry · doi:10.15406/jpcpy.2023.14.00738 · Cited by 3
Acute and Long-Term Effects of Ayahuasca on (Higher-Order) Cognitive Processes
Mason, N. L., & Kuypers, K. P. C. (2021) · Springer eBooks · doi:10.1007/978-3-030-55688-4_7 · Cited by 4
Sueur, C. (2018) · Psychotropes · doi:10.3917/psyt.233.0125 · Cited by 6
Psychedelics and schizophrenia: A mystery in history
Haden, M., Woods, B., & Paschall, S. A. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00277 · Cited by 6
Matos, T. S., Zandonadi, F. D. S., Silva, A., Soares, S. D., Lima, A. D. S., Pastore, G. M., Porcari, A. M., & Sussulini, A. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2420059 · Cited by 4
Kase, M., Kaup, K., & Aru, J. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251412012 · Cited by 2
“The scarcity of placebo-controlled studies on ayahuasca could be explained by the fact that these studies are often conducted in cer-emonial settings with open-label design (dos Santos et al., 2016).”
de Sousa, P. C. M., de Sousa, I. N. A., Leite, L. L. L., Oliveira, A. L. O., Souza, K. A. D. S., Soares, J. D. S., Viana, M. D. R., & do Amaral, M. P. D. M. (2021) · Research Society and Development · doi:10.33448/rsd-v10i4.14251 · Cited by 3
Use of psychedelics in the Czech Republic: results of recent population surveys
Chomynová, P., Kočárová, R., Kňažek, F., Plevková, M., Bláhová, B., Valeš, K., & Mravčík, V. (2022) · Central European Journal of Public Health · doi:10.21101/cejph.a7079 · Cited by 2
Utilization of Ketamine for Major Depression
Dao, R., & Aggarwal, A. (2023) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2023.00027 · Cited by 2
Tradiční amazonská medicína v české subkultuře
Horák, M., & Vosáhlová, Š. (2016) · Anthropologia integra · doi:10.5817/ai2016-2-47 · Cited by 3
Could Psychedelics Treat Neuropathic Chronic Pain?
(2023) · Neurological Sciences and Neurosurgery · doi:10.47275/2692-093x-130 · Cited by 1
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0012 · Cited by 2
Ketamine and Electroconvulsive Therapy for Depression
Andrade, C. (2018) · Journal of Neurosurgical Anesthesiology · doi:10.1097/ana.0000000000000524 · Cited by 2
LSD induces increased signalling entropy in rats’ prefrontal cortexPreprint
Savino, A., & Nichols, C. D. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.23.449556 · Cited by 2
Simulated synapse loss induces depression-like behaviors in deep reinforcement learning
Chalmers, E., Duarte, S., Al-Hejji, X., Devoe, D. J. A., Gruber, A. J., & McDonald, R. J. (2024) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2024.1466364 · Cited by 1
Lodetti, G., Réus, G. Z., & Rico, E. P. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.01.022 · Cited by 1
Brache, K., & Diazgranados, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1729887 · Cited by 1
van der Heijden, K. V., Makai‐Bölöni, S., Inamdar, A., Otto, M. E., Hegle, A. P., Aa, L., Zuiker, R. G. J. A., Bohoslavsky, R., de Kam, M. L., James, E., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261473451 · Cited by 2
Possível uso da Psilocibina no tratamento psiquiátrico, incluindo sequelas da COVID-19
Bonifácio, M. C. A. C., Bento, P. B. B., Trevisan, K., Cristina-Pereira, R., Magri, M. P. D. F., & Aversi‐Ferreira, T. A. (2021) · Research Society and Development · doi:10.33448/rsd-v10i11.19259 · Cited by 2
Jayasree, M., Athira, & Thenmozhi, K. (2023) · Kongunadu Research Journal · doi:10.26524/krj.2023.16 · Cited by 1
“Psychoactive compounds like DMT (Dimethyltryptamine) from Psychotria viridis , MAOIs from Banisteriopsis caapi vine are also effective in treating depression and anxiety [4].”
BackgroundFundamentals of the septo-hippocampal system
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0009 · Cited by 1
Memory and the septo-hippocampal system
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0008 · Cited by 1
Noori, T., Shirooie, S., Khodarahmi, Z., Sureda, A., Akkol, E. K., & Farzaei, M. H. (2025) · Journal of Reports in Pharmaceutical Sciences · doi:10.5812/jrps-148619 · Cited by 1
Novel harmala-ocudelic tuning (HOT) for ocular disorders
Lansky, E. S. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109834 · Cited by 1
(2021) · Revista de Psiquiatría del uruguay · doi:10.46706/psi/85.1.4 · Cited by 8
Psychodeliki - lepsza alternatywa leczenia depresji?
Gołembiowska, K. (2021) · Nauka · doi:10.24425/nauka.2021.137644 · Cited by 2
“…ą ce, mimo ż e badania te obarczone by ł y b łę dami metodycznymi, takimi jak brak odpowiednich grup kontrol-nych, znaczne ró ż nice w dawkowaniu oraz czasie prowadzonych obserwacji, nieprawi-d ł owe kryteria doboru pacjentów ze wzgl ę du na p ł e ć i histori ę terapii (dos Santos et al. 2016 ).”
Lim, C. H., Kangas, B. D., & Bergman, J. (2018) · doi:10.22186/jyi.35.2.45-49 · Cited by 1
06 - CASE-REPORT OF A ‘TEA CEREMONY’ WITH AYAHUASCA: AN EMOTIONAL ROLLERCOASTER
Arts, M. H. L., de Jonge, L., & Petrykiv, S. I. (2019) · doi:10.26226/morressier.5c642bdc9ae8fb00131ce508 · Cited by 1
Psilocybin-Assisted Psychotherapy: Treating Depression and Anxiety with Mushrooms
Beck, S. (2020) · Dominican Scholar (Dominican University of California) · doi:10.33015/dominican.edu/2020.pas.10 · Cited by 1
“For thousands of years, psilocybin has been used in religious, medicinal, and ceremonial practices around the world.(8) It was first isolated and synthesized by the Swiss chemist Albert”
BackgroundKelley, D. P., Venable, K. E., Billac, G. B., Destouni, A., Ebenezer, P. J., Stadler, K., Nichols, C. D., Barker, S. A., & Francis, J. (2021) · Research Square · doi:10.21203/rs.3.rs-602961/v1 · Cited by 1
Kelley, D. P. (2022) · Louisiana State University · doi:10.31390/gradschool_dissertations.5761 · Cited by 1
On Neuroimmunology and Brain Function: Experimental and Clinical Studies
Strenn, N. (2019) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Ayahuasca as a Versatile Therapeutic Agent: From Molecules to Metacognition and Back
Valle, M., Domínguez‐Clavé, E., Elices, M., Pascual, J. C., Soler, J., Morales-Garcia, J. A., Pérez‐Castillo, A., & Riba, J. (2021) · Springer eBooks · doi:10.1007/978-3-030-55688-4_1 · Cited by 1
Meil, W. M., Farrell, W., & Satti, R. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98514
The Effect of Psilocybin on Personality
LaBua, R. (2021) · CUNY Academic Works (City University of New York) · Cited by 1
601 津八幡宮祭礼絵巻からみる近世初期津城下町と町屋 : ニューヨークパブリックライブラリー蔵 津八幡宮祭礼絵巻の建築史的研究(歴史・意匠)
副島, 正., & 菅原, 洋. (2005) · 東海支部研究報告集 · Cited by 1
Mason, N. L. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210608nm · Cited by 1
Hollander, E., & Uzunova, G. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735236753.793581300
Márquez, B. D. P., & Dietl, B. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.06.035
Faculty Opinions recommendation of Psychedelics promote structural and functional neural plasticity.
Chapman, E. R., & Vevea, J. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733441066.793547403
Novel Approaches for Treating Anxiety Disorders
Sturman, D. A., Kaufman, M. L., Bigony, C. E., & Ressler, K. J. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0039
SUBJECTIVE EXPERIENCES OF CLASSIC PSYCHEDELIC SUBSTANCES USERS
Bienemann, B. (2022) · doi:10.17771/pucrio.acad.59337 · Cited by 1
Relation between Psychedelic and Transcendental Experiences
Travis, F. T. (2022) · International Journal of Psychological Studies · doi:10.5539/ijps.v14n4p31
“Another meta-analysis reported that psychedelic-assisted therapy using ayahuasca, psilocybin or LSD led to significant improvements in treatment-resistant depression, anxiety and depression, and tobacco and alcohol dependence (Dos Santos et al., 2016).”
BackgroundCaldararo, N. (2022) · Springer eBooks · doi:10.1007/978-3-031-13745-7_2
Kratina, S., Lo, C., Schwartz, R. D., Strıke, C., Jopling, S. A., Nayfeh, A., & Rush, B. R. (2023) · doi:10.31234/osf.io/4gfyd
PRODUÇÃO CIENTÍFICA SOBRE A AYAHUASCA NA WEB OF SCIENCE: UMA ANÁLISE BIBLIOMÉTRICA
Soeiro, H. M. D. A. D. N. (2023) · Revista Científica FAEMA · doi:10.31072/rcf.v14i2.1386 · Cited by 1
Breeksema, J. J. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.912040905 · Cited by 1
Pot fi substanţele psihedelice o nouă opţiune terapeutică pentru tulburările psihice?
Boloș, A., Nedelcu, C. E., & Alexinschi, O. (2024) · Psihiatru ro · doi:10.26416/psih.76.1.2024.9463
What do hippocampal cell fields represent?
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0007
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0001 · Cited by 1
The neurology of anxiety—planning circuits
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0011
A theory of the septo-hippocampal system (SHS)
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0010
Symptoms and syndromes of anxiety
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0013
The neurology of anxiety—survival circuits
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0006
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0002
The treatment of anxiety and fear disorders
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0014
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.002.0011
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0015
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.002.0009
The anxiolytic drugs—our key tool
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0004
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0003
List of online appendices and reviews
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.002.0010
A conceptual theory of the goal inhibition system
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.003.0005
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.002.0006
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.002.0004
McNaughton, N., & Gray, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780198843313.002.0005
Chalmers, E., Duarte, S., Al-Hejji, X., Devoe, D. J. A., Gruber, A. J., & McDonald, R. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.01.596905
Ego dissolution in psychedelic experience
Gerrans, P. (2024) · Oxford University Press eBooks · doi:10.1093/9780191994395.003.0007
Mattu, J., & Sullivan, J. A. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780192898371.003.0007
Microdosing Psychedelics as a Promising New Pharmacotherapeutic
Kuypers, K. P. C. (2024) · Springer eBooks · doi:10.1007/978-3-031-61992-2_26
Totomanova, I., Haijen, E. C. H. M., Hurks, P. P. M., Ramaekers, J. G., & Kuypers, K. P. C. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.03.002
Arabmoazzen, S., Mirshekar, M. A., KHaleghpoor, K., Esfahlani, M. A., & Badini, F. (2025) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-025-01758-3
“One of the most critical concerns in these drugs is their harmful effects [7, 8].”
« Ayahuasca sans ayahuasca »: Du clientélisme chamanique à une patientèle en devenir
Sánchez, J. L., & Cappo, S. M. (2025) · Drogues santé et société · doi:10.7202/1118071ar
Saudemont, G., Brunet-Jailly, J., & Coz, P. L. (2025) · Éthique & Santé · doi:10.1016/j.etiqe.2025.06.001
Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review
van der Meer, P. B., Schukking, N., Dik, M., van Reemst, A., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., Verboeket, S. O., de Waal, M. M., Goudriaan, A. E., et al. (2025) · Psychedelic Medicine · doi:10.1177/28314425251364182
Reuter, T. K., Sears, F., & Gezon, L. L. (2025) · Anthropology of Consciousness · doi:10.1111/anoc.70026
Ford, S. A., Ness, R. W., Kwon, M., Ro, D.-K., & Phillips, M. A. (2024) · Figshare · doi:10.6084/m9.figshare.27140623
Ford, S. A., Ness, R. W., Kwon, M., Ro, D.-K., & Phillips, M. A. (2024) · Figshare · doi:10.6084/m9.figshare.27140632
Ford, S. A., Ness, R. W., Kwon, M., Ro, D.-K., & Phillips, M. A. (2024) · Figshare · doi:10.6084/m9.figshare.27140617
Ford, S. A., Ness, R. W., Kwon, M., Ro, D.-K., & Phillips, M. A. (2024) · Figshare · doi:10.6084/m9.figshare.27140629
Ford, S. A., Ness, R. W., Kwon, M., Ro, D.-K., & Phillips, M. A. (2024) · Figshare · doi:10.6084/m9.figshare.27140620
Innovative Pharmacological Approaches to Eating Disorder Treatment
Keshen, A. R., Touyz, S. W., Lacroix, E., Hay, P., & McElroy, S. L. (2025) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2025.08.014
Medicinal Mushrooms and Mental Disorders: How Mushrooms Affect Anxiety and Depression
Tarki, A., Hajikarim‐Hamedani, A., Rassa, S., & Khosravi, S. (2025) · Nutritional neurosciences · doi:10.1007/978-981-95-2774-8_6
Noorani, T. N. (2026) · The politics of mental health and illness · doi:10.1007/978-3-032-06313-7_10
Pokorska, J., Piestrzyńska-Kajtoch, A., Adamczyk, K., Kułaj, D., Łapczyński, M., Żmuda, P., & Bauer, E. A. (2026) · Annals of Animal Science · doi:10.2478/aoas-2025-0102
“Although the mechanisms of behavioural disorders are difficult to define, it is now known that too many 5HT 2A receptors can lead to intensified emotions and anxiety (Dos Santos et al., 2016).”
Psychedelics and Autism Therapy: A Review of Current Research and Future Directions
Gondi, C. S., Gnanamony, M., Gondi, T. P., Nersesyan, L., & Demirkhanyan, L. H. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48040417
Bray, E., Glatfelter, G. C., Maitland, A. D., Gonzalez, N. R., Walther, D. M., Yacoub, J., Baumann, M. H., & von Salm, J. L. (2026) · ACS Omega · doi:10.1021/acsomega.6c02996
Metadata
- Authors
- dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C.
- Affiliations
- Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Hospital das Clínicas, Terceiro Andar, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, Brazil
- Department of Neuroscience and Behavior, Ribeirão Preto Medical School, University of São Paulo, SP, Brazil National Institute for Translational Medicine (INCT-TM), CNPq, Brazil
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (BR)
- Centre d’Investigació de Medicaments, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2016-03-18
- Volume
- 6
- Issue
- 3
- Pages
- 193-213
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC4910400
- OpenAlex
- W2325558246
- Cited by
- 306
- References
- 196
- Citations by year
- 2026: 18 · 2025: 17 · 2024: 50 · 2023: 28 · 2022: 32 · 2021: 44 · 2020: 35 · 2019: 27 · 2018: 29 · 2017: 20 · 2016: 5
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- ayahuasca, psilocybin, lysergic acid diethylamide, antidepressant effects, anxiolytic effects, treatment-resistant depression, anxiety disorders, drug addiction, tobacco dependence, alcoholism, psychedelics, mood disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.